MC
RIGL icon

Maverick Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Maverick Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,112
Closed -$517K – 817
2021
Q1 		$517K Buy
+15,112
New +$598K ﹤0.01% 384

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Maverick Capital's RIGL Position: Q2 2021 in Review

Maverick Capital sold out of Rigel Pharmaceuticals (RIGL) in Q2 2021, closing a stake of 15,112 shares — an estimated $517K sold.

Maverick Capital first reported a position in RIGL in Q1 2021 and held it in 1 quarter. The position peaked at $517K in Q1 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q2 2021.

  • Maverick Capital reported no remaining Rigel Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Maverick Capital sold 15,112 Rigel Pharmaceuticals shares in Q2 2021, an estimated $517K.
  • Maverick Capital first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Maverick Capital's Rigel Pharmaceuticals position peaked at $517K in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2021.

Based on Maverick Capital's 13F filing for Q2 2021, filed 16 Aug 2021.